FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

RR Bartlett

Research Profile

Chemicals & Drugs

Living Beings

Disorders

Physiology

Graft Rejection

Procedures

Co-author Network

Publications

TOP 3
HU Schorlemmer; R Kurrle; R Schleyerbach; RR Bartlett
Generation of O2- radicals in macrophages can be inhibited in vitro and in vivo by derivatives of leflunomide's primary metabolite.
HU Schorlemmer; U Milbert; D Zeitter; G Haun; M Wunschel; RR Bartlett
Cell cycle regulation and inhibition of de novo pyrimidine biosynthesis by leflunomide.
HU Schorlemmer; R Kurrle; R Schleyerbach; RR Bartlett
Disease-modifying activity of malononitrilamides, derivatives of leflunomide's active metabolite, on models of rheumatoid arthritis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of RR Bartlett (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

1999: HU Schorlemmer; R Kurrle; R Schleyerbach; RR Bartlett
Generation of O2- radicals in macrophages can be inhibited in vitro and in vivo by derivatives of leflunomide's primary metabolite.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1999;48 Suppl 2():S117-8.
1999: HU Schorlemmer; U Milbert; D Zeitter; G Haun; M Wunschel; RR Bartlett
Cell cycle regulation and inhibition of de novo pyrimidine biosynthesis by leflunomide.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1999;48 Suppl 2():S115-6.
1999: HU Schorlemmer; R Kurrle; R Schleyerbach; RR Bartlett
Disease-modifying activity of malononitrilamides, derivatives of leflunomide's active metabolite, on models of rheumatoid arthritis.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1999;48 Suppl 2():S113-4.
1999: HU Schorlemmer; R Kurrle; R Schleyerbach; RR Bartlett
In vivo lymphoproliferation in the popliteal lymph node (PLN) assay can be inhibited by leflunomide's active metabolite A77 1726.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1999;48 Suppl 2():S111-2.
1999: HU Schorlemmer; RR Bartlett; J K Lindner; R Kurrle
Coadministration of malononitrilamides and tacrolimus induces tolerance in a rat skin allograft model.
Transplantation proceedings 1999;31(1-2):1184-8.
1999: HU Schorlemmer; RR Bartlett; R Kurrle
Malononitrilamides prevent the generation of oxygen radicals in mononuclear phagocytes and graft rejection in a rat model.
Transplantation proceedings 1999;31(1-2):851-3.
1998: HU Schorlemmer; RR Bartlett
Modulation of immunoglobulin dysregulation in graft versus host-and systemic lupus erythematosus-like diseases by malononitrilamides.
Transplantation proceedings 1998;30(8):4153-5.
1998: HU Schorlemmer; RR Bartlett; R Schleyerbach
Immunomodulatory activity of malononitrilamides, derivatives of leflunomide's primary metabolite, on models of experimental rheumatoid arthritis.
Transplantation proceedings 1998;30(8):4137-9.
1998: HU Schorlemmer; RR Bartlett; J K Lindner; R Kurrle
Long-term allograft survival and tolerance induction by the synergistic activity of malononitrilamides and tacrolimus.
Transplantation proceedings 1998;30(8):4099-103.
1998: HU Schorlemmer; RR Bartlett; R Kurrle
Inhibition of alloreactivity in the popliteal lymph node assay by malononitrilamides.
Transplantation proceedings 1998;30(4):968-70.
1997: HU Schorlemmer; RR Bartlett
Prevention of the development of murine systemic lupus erythematosus (SLE)-like diseases by the malononitrilamides MNA 279 and MNA 715.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1997;46 Suppl 2():S167-8.
1997: HU Schorlemmer; R Kurrle; RR Bartlett
Various graft vs. host diseases (GvHD) in rodents can be prevented and treated by malononitrilamides (MNAs).
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1997;46 Suppl 2():S165-6.
1997: HU Schorlemmer; RR Bartlett
Malononitrilamides (MNA 279 and MNA 715) have therapeutic activity in acute and chronic relapsing experimental allergic encephalomyelitis (EAE).
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1997;46 Suppl 2():S163-4.
1997: HU Schorlemmer; RR Bartlett; R Kurrle
Analogues of leflunomide's primary metabolite, the malononitrilamides, prevent the development of graft-versus-host disease.
Transplantation proceedings 1997;29(1-2):1298-301.
1997: HU Schorlemmer; RR Bartlett
Therapeutic activity of malononitrilamides (MNA 279 and MNA 715) on acute and chronic, relapsing, experimental, allergic encephalomyelitis (EAE).
Drugs under experimental and clinical research 1997;23(5-6):175-81.
1997: HU Schorlemmer; R Kurrle; RR Bartlett
The new immunosuppressants, the malononitrilamides MNA 279 and MNA 715, inhibit various graft-vs.-host diseases (GvHD) in rodents.
Drugs under experimental and clinical research 1997;23(5-6):167-73.
1996: M Dimitrijevic; RR Bartlett
Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of mononuclear cells in rheumatoid arthritis.
Transplantation proceedings 1996;28(6):3086-7.
1996: RR Bartlett; S Brendel; T Zielinski; HU Schorlemmer
Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis.
Transplantation proceedings 1996;28(6):3074-8.
1996: S Stosić-Grujicić; M Dimitrijević; RR Bartlett
A novel immunomodulating agent--leflunomide inhibits experimental autoimmune diabetes in mice.
Transplantation proceedings 1996;28(6):3072-3.
1996: HU Schorlemmer; R Kurrle; RR Bartlett
Malononitrilamides inhibit the development of various murine graft-vs-host diseases.
Transplantation proceedings 1996;28(6):3043-7.
1996: HU Schorlemmer; S Brendel; RR Bartlett
Malononitrilamides prevent the development of murine systemic lupus erythematosus-like diseases in BDF1 hybrid mice and MRL/lpr autoimmune mice.
Transplantation proceedings 1996;28(6):3040-2.
1996: M Dimitrijevic; RR Bartlett
Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of peripheral blood and synovial fluid mononuclear cells in rheumatoid arthritis.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1996;45(11):550-6.
1995: T Zielinski; D Zeitter; S Müller; RR Bartlett
Leflunomide, a reversible inhibitor of pyrimidine biosynthesis?
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1995;44 Suppl 2():S207-8.
1994: C Mrowka; G H Thoenes; K H Langer; RR Bartlett
Prevention of the acute graft-versus-host disease (GVHD) in rats by the immunomodulating drug leflunomide.
Annals of hematology 1994;68(4):195-9.
1993: G Weber; F Link; E Ferber; P G Munder; D Zeitter; RR Bartlett; K Nixdorff
Differential modulation of the effects of lipopolysaccharide on macrophages by a major outer membrane protein of Proteus mirabilis.
Journal of immunology (Baltimore, Md. : 1950) 1993;151(1):415-24.
1993: HU Schorlemmer; F R Seiler; RR Bartlett
Prolongation of allogeneic transplanted skin grafts and induction of tolerance by leflunomide, a new immunosuppressive isoxazol derivative.
Transplantation proceedings 1993;25(1 Pt 1):763-7.
1993: RR Bartlett; H Anagnostopulos; T Zielinski; T Mattar; R Schleyerbach
Effects of leflunomide on immune responses and models of inflammation.
Springer seminars in immunopathology 1993;14(4):381-94.
1993: T Zielinski; H J Müller; RR Bartlett
Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers.
Agents and actions 1993;38 Spec No():C80-2.
1992: Tibor T Glant; Katalin Mikecz; RR Bartlett; F Deák; Eugene Thonar; J M Williams; T Mattar; Klaus E Kuettner; R Schleyerbach
Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide.
Immunopharmacology 1992;23(2):105-16.
1992: G Weber; D Heck; RR Bartlett; K Nixdorff
Modulation of effects of lipopolysaccharide on macrophages by a major outer membrane protein of Proteus mirabilis as measured in a chemiluminescence assay.
Infection and immunity 1992;60(3):1069-75.
1991: HU Schorlemmer; RR Bartlett; F R Seiler
15-Deoxyspergualin (15-DOS) has a curative effect on the development of SLE-like autoimmune disease in MRL/1 mice.
Agents and actions 1991;34(1-2):151-5.
1991: C C Küchle; G H Thoenes; K H Langer; HU Schorlemmer; RR Bartlett; R Schleyerbach
Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent.
Transplantation proceedings 1991;23(1 Pt 2):1083-6.
1991: RR Bartlett; M Dimitrijevic; T Mattar; T Zielinski; T Germann; E Rüde; G H Thoenes; C C Küchle; HU Schorlemmer; E Bremer
Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection.
Agents and actions 1991;32(1-2):10-21.
1991: HU Schorlemmer; RR Bartlett; R Schleyerbach; F R Seiler
Immunosuppressive activity of 15-deoxyspergualin (15-DOS) on various models of rheumatoid arthritis.
Drugs under experimental and clinical research 1991;17(10-11):471-84.
1990: HU Schorlemmer; RR Bartlett; E Wolf; F R Seiler
Prolongation of allogeneic transplanted skin grafts by A85 4777, a new immunosuppressive homopiperazine derivative.
Transplantation proceedings 1990;22(4):1671-3.
1990: RR Bartlett; R Schleyerbach; K U Schorlemmer; E Wolf
Pharmacological profile of A85 4777, a novel antiinflammatory agent with nonclassical immunosuppressive properties.
Transplantation proceedings 1990;22(4):1666-70.
1990: RR Bartlett; R Schleyerbach; Klaus Ulrich Weithmann; W Thorwart
Pharmacological profile of HWA-131, a novel antiinflammatory agent with immunomodulating properties.
Agents and actions 1990;29(1-2):71-3.
1989: G H Thoenes; Thomas Sitter; K H Langer; RR Bartlett; R Schleyerbach
Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats.
International journal of immunopharmacology 1989;11(8):921-9.
1989: RR Bartlett; U Gebert; B Kerékjártó; R Schleyerbach; W Thorwart; Klaus Ulrich Weithmann
Substituted 3-phenyl-7H-thiazolo(3,2-b)(1,2,4)triazin-7-ones as antiinflammatory agents with immunomodulating properties.
Drugs under experimental and clinical research 1989;15(11-12):521-6.
1987: G Dickneite; HU Schorlemmer; E Weinmann; RR Bartlett; H H Sedlacek
Skin transplantation in rats and monkeys: evaluation of efficient treatment with 15-deoxyspergualin.
Transplantation proceedings 1987;19(5):4244-7.
1985: RR Bartlett; R Schleyerbach
Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity--I. Disease modifying action on adjuvant arthritis of the rat.
International journal of immunopharmacology 1985;7(1):7-18.
1984: M Limbert; RR Bartlett; G Dickneite; N Klesel; HU Schorlemmer; G Seibert; I Winkler; E Schrinner
Cefodizime, an aminothiazolyl cephalosporin. IV. Influence on the immune system.
The Journal of antibiotics 1984;37(12):1719-26.